98%
921
2 minutes
20
Purpose: To evaluate the feasibility of translating clinical lung stereotactic ablative radiotherapy (SAbR) templates from Ethos1.1 to Ethos2.0, leveraging new features to facilitate dose fall-off and automate patient-specific beam arrangement. This study aims to streamline planning processes and support broader adoption of online adaptive radiotherapy (ART) for lung SAbR.
Methods: We selected fifteen patients previously treated with adaptive lung SAbR using the Ethos1.1 system, each receiving 40-60 Gy in 5 fractions. Plans were reoptimized in Ethos2.0 using identical parameters (rIMRT) to their clinical counterpart. To evaluate new integrated features, we utilized high-fidelity (HF) mode with and without automatic treatment geometry selection (HF-cIMRT, HF-aIMRT/VMAT). These strategies were compared to assess the impact of Ethos2.0's new features on plan quality and efficiency using RTOG-based metrics and enhanced plan deliverability analysis. Statistical significance was assessed using paired Student's t-tests (α = 0.05).
Results: All plans reoptimized in Ethos2.0 demonstrated acceptable plan quality. No statistically significant differences in maximum organ-at-risk doses were observed between evaluated strategies and the clinical plan. For complex cases, human-selected beam geometry proved superior to automated geometry. HF-enabled plans significantly reduced total monitor units, with HF-aVMAT, HF-cIMRT, and HF-aIMRT reporting 3142.4 ± 997.4 (p < 0.001), 3401.8 ± 516.1 (p < 0.001), and 3225.6 ± 484.2 (p < 0.001) compared to clinical 5424.9 ± 1353.4. A trade-off was observed in conformity index, which was 1.06 ± 0.08 (p = 0.006), 1.05 ± 0.06 (p = 0.003), and 1.03 ± 0.05 (p = 0.05) for HF-aIMRT, HF-cIMRT, and HF-aVMAT plans compared to clinical 1.01 ± 0.03.
Conclusion: Lung SAbR planning strategies can be effectively transitioned from Ethos1.1 to Ethos2.0, improving workflow efficiency with high-fidelity mode and minor adjustments. Automated beam geometry tools enhance planner efficiency for both IMRT and VMAT. To address increased ART workload and staffing demands, leveraging integrated automation tools is essential. The planning strategies presented in this study are straightforward and reproducible for ART-enabled clinics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260260 | PMC |
http://dx.doi.org/10.1002/acm2.70195 | DOI Listing |
Int J Radiat Oncol Biol Phys
September 2025
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Smoluchowskiego 17 str., 80-215, Gdańsk, Poland.
Background: Stereotactic Ablative Radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC) can stimulate an immune response against cancer. We evaluated changes in peripheral lymphocyte subpopulations and cytokines levels after SABR in patients with early-stage NSCLC. We examined how these changes relate to overall survival (OS) and disease-free survival (DFS).
View Article and Find Full Text PDFBMC Cancer
September 2025
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Background: Anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) immunotherapy promotes systemic anti-tumor immunity through expanding neoantigen-specific CD8 + T cells, but it is less effective in patients with liver metastases. Nearly 20% of non-small cell lung cancer (NSCLC) patients develop liver metastases, and these patients are characterized by fewer and less active effector T cells. Preclinical work has shown that liver metastases cause systemic immunosuppression through siphoning neoantigen-specific CD8 + T cells from systemic circulation with subsequent macrophage-mediated intrahepatic death.
View Article and Find Full Text PDFBMC Cancer
August 2025
Department of Radiation Oncology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Background: Recurrent ovarian cancer is often treated with chemotherapy, but many patients experience multiple recurrences with progressively shorter intervals and poorer prognosis. Repeated chemotherapy reduces patients' quality of life. Stereotactic Ablative Radiation Therapy for Recurrent Ovarian Cancer (SABR-ROC) (KGOG3064/KROG 2204) is an ongoing trial investigating the clinical efficacy of stereotactic ablative radiation therapy (SABR) for recurrent ovarian cancer.
View Article and Find Full Text PDFRadiother Oncol
August 2025
Radiation Oncology, University Medical Center Groningen (UMCG), Groningen, the Netherlands.
Background And Purpose: Accurate delineation of the Gross Tumor Volume (GTV) and the Internal Target Volume (ITV) in early-stage lung tumors is crucial in Stereotactic Body Radiation Therapy (SBRT). Traditionally, the ITVs, which account for breathing motion, are generated by manually contouring GTVs across all breathing phases (BPs), a time-consuming process. This research aims to streamline this workflow by developing a deep learning algorithm to automatically delineate GTVs in all four-dimensional computed tomography (4D-CT) BPs for early-stage Non-Small Cell Lung Cancer Patients (NSCLC).
View Article and Find Full Text PDFRadiother Oncol
August 2025
Department of Radiation Oncology, Centre Eugène Marquis, Ille-et-Vilaine, Rennes, France.